From Brand to Generic: Comprehensive Reverse Engineering Methodologies in Drug Development
The transition of a pharmaceutical product from a patent-protected brand-name drug to a competitive generic is a cornerstone of modern […]
The transition of a pharmaceutical product from a patent-protected brand-name drug to a competitive generic is a cornerstone of modern […]
In pharmaceutical development, where a single patent can underpin a franchise worth tens of billions of dollars, the concept of
Assessing PTAB Risk: When is a Drug Patent Truly Secure? Read Post »
This report is designed for the strategic executive and the savvy in-house counsel. It’s a guide to moving beyond the
In the pharmaceutical industry value is created not just in the laboratory but on the complex chessboard of international trade
Leveraging Patent Term Discrepancies for Parallel Trade and Licensing Read Post »
Let’s be candid. The era of the single-modality blockbuster, the “one-pill-fits-all” small molecule or the “one-target” monoclonal antibody, is drawing
Mastering the New Rules of Small Molecule-Biologic Combination Patents Read Post »
The Multi-Trillion-Dollar Pivot If you are an IP strategist, a business development leader, or an R&D chief in the pharmaceutical
The New Biologic Gold Rush: Patent Strategy in the Age of Amgen v. Sanofi Read Post »
Introduction: The High-Stakes Game of Pharmaceutical Lifecycles The lifecycle of a drug is a story of immense investment, groundbreaking science,
The intellectual property landscape for small molecule pharmaceuticals has never been more challenging or critical. As R&D costs soar and
Patenting Strategies for Small Molecule Drugs to Maximize ROI and Market Exclusivity Read Post »
For too long, Africa has been viewed through a monolithic lens—a single, challenging market characterized more by risk than by
Get fresh news and insights, drug patent expirations & more…